PT3781200T - Anticorpos para radionuclídeos quelados - Google Patents
Anticorpos para radionuclídeos queladosInfo
- Publication number
- PT3781200T PT3781200T PT197230147T PT19723014T PT3781200T PT 3781200 T PT3781200 T PT 3781200T PT 197230147 T PT197230147 T PT 197230147T PT 19723014 T PT19723014 T PT 19723014T PT 3781200 T PT3781200 T PT 3781200T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- chelated radionuclides
- chelated
- radionuclides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658468P | 2018-04-16 | 2018-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3781200T true PT3781200T (pt) | 2024-07-19 |
Family
ID=66476592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197230147T PT3781200T (pt) | 2018-04-16 | 2019-04-16 | Anticorpos para radionuclídeos quelados |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20220389116A1 (enExample) |
| EP (2) | EP4406607A3 (enExample) |
| JP (3) | JP7475283B2 (enExample) |
| KR (1) | KR102884852B1 (enExample) |
| CN (1) | CN112261952A (enExample) |
| AR (1) | AR115053A1 (enExample) |
| AU (1) | AU2019254537B2 (enExample) |
| BR (1) | BR112020021061A2 (enExample) |
| CA (1) | CA3096338A1 (enExample) |
| CL (1) | CL2020002680A1 (enExample) |
| CR (1) | CR20200548A (enExample) |
| DK (1) | DK3781200T3 (enExample) |
| ES (1) | ES2985352T3 (enExample) |
| FI (1) | FI3781200T3 (enExample) |
| HR (1) | HRP20241013T1 (enExample) |
| HU (1) | HUE067622T2 (enExample) |
| IL (1) | IL277575B2 (enExample) |
| LT (1) | LT3781200T (enExample) |
| MA (1) | MA52545B1 (enExample) |
| MX (1) | MX2020010954A (enExample) |
| MY (1) | MY207044A (enExample) |
| PE (1) | PE20210442A1 (enExample) |
| PL (1) | PL3781200T3 (enExample) |
| PT (1) | PT3781200T (enExample) |
| RS (1) | RS65753B1 (enExample) |
| SG (1) | SG11202010066TA (enExample) |
| SI (1) | SI3781200T1 (enExample) |
| TW (1) | TWI874314B (enExample) |
| UA (1) | UA130541C2 (enExample) |
| WO (1) | WO2019201959A1 (enExample) |
| ZA (1) | ZA202006121B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2022008688A1 (en) * | 2020-07-10 | 2022-01-13 | F. Hoffmann-La Roche Ag | Antibodies which bind to cancer cells and target radionuclides to said cells |
| PE20240690A1 (es) | 2021-01-12 | 2024-04-10 | Hoffmann La Roche | Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas |
| CN116744981A (zh) * | 2021-01-13 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 组合疗法 |
| AU2022207624A1 (en) * | 2021-01-13 | 2023-07-13 | F. Hoffmann-La Roche Ag | Combination therapy |
| JP2024546810A (ja) | 2021-12-15 | 2024-12-26 | ワイ－マブス セラピューティクス， インコーポレイテッド | 多量体化が低減されているｓｃＦｖ及び抗体 |
| WO2024099526A1 (en) | 2022-11-08 | 2024-05-16 | Y-Mabs Therapeutics, Inc. | Bispecific antibody compounds |
| IL330142A (en) | 2024-02-20 | 2026-08-01 | F Hoffmann La Roche Ag | New Antibodies for Pre-Targeting and Their Uses |
| WO2026041568A1 (en) | 2024-08-20 | 2026-02-26 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and dotam |
| WO2026082710A1 (en) | 2024-10-16 | 2026-04-23 | F. Hoffmann-La Roche Ag | Small molecule-inducible recombinant receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2943299A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
| WO2016102536A1 (en) * | 2014-12-23 | 2016-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza |
| WO2016126950A1 (en) * | 2015-02-05 | 2016-08-11 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| WO2016130539A2 (en) * | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| JP7044700B2 (ja) * | 2015-10-02 | 2022-03-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子 |
| EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| PL3781201T3 (pl) * | 2018-04-16 | 2026-02-23 | Orano Med Manufacturing SAS | Przeciwciała dla chelatowanych radionuklidów i środków klarujących |
-
2019
- 2019-04-16 KR KR1020207032824A patent/KR102884852B1/ko active Active
- 2019-04-16 MY MYPI2020005339A patent/MY207044A/en unknown
- 2019-04-16 MX MX2020010954A patent/MX2020010954A/es unknown
- 2019-04-16 ES ES19723014T patent/ES2985352T3/es active Active
- 2019-04-16 JP JP2020556869A patent/JP7475283B2/ja active Active
- 2019-04-16 SI SI201930792T patent/SI3781200T1/sl unknown
- 2019-04-16 FI FIEP19723014.7T patent/FI3781200T3/fi active
- 2019-04-16 HR HRP20241013TT patent/HRP20241013T1/hr unknown
- 2019-04-16 CR CR20200548A patent/CR20200548A/es unknown
- 2019-04-16 AU AU2019254537A patent/AU2019254537B2/en active Active
- 2019-04-16 SG SG11202010066TA patent/SG11202010066TA/en unknown
- 2019-04-16 CA CA3096338A patent/CA3096338A1/en active Pending
- 2019-04-16 RS RS20240810A patent/RS65753B1/sr unknown
- 2019-04-16 WO PCT/EP2019/059856 patent/WO2019201959A1/en not_active Ceased
- 2019-04-16 US US17/048,073 patent/US20220389116A1/en not_active Abandoned
- 2019-04-16 TW TW108113285A patent/TWI874314B/zh active
- 2019-04-16 AR ARP190101005A patent/AR115053A1/es unknown
- 2019-04-16 CN CN201980038709.1A patent/CN112261952A/zh active Pending
- 2019-04-16 DK DK19723014.7T patent/DK3781200T3/da active
- 2019-04-16 IL IL277575A patent/IL277575B2/en unknown
- 2019-04-16 EP EP24169799.4A patent/EP4406607A3/en active Pending
- 2019-04-16 BR BR112020021061-7A patent/BR112020021061A2/pt unknown
- 2019-04-16 LT LTEPPCT/EP2019/059856T patent/LT3781200T/lt unknown
- 2019-04-16 PL PL19723014.7T patent/PL3781200T3/pl unknown
- 2019-04-16 HU HUE19723014A patent/HUE067622T2/hu unknown
- 2019-04-16 PE PE2020001551A patent/PE20210442A1/es unknown
- 2019-04-16 EP EP19723014.7A patent/EP3781200B1/en active Active
- 2019-04-16 PT PT197230147T patent/PT3781200T/pt unknown
- 2019-04-16 MA MA52545A patent/MA52545B1/fr unknown
- 2019-04-16 UA UAA202007212A patent/UA130541C2/uk unknown
-
2020
- 2020-10-02 ZA ZA2020/06121A patent/ZA202006121B/en unknown
- 2020-10-16 CL CL2020002680A patent/CL2020002680A1/es unknown
-
2024
- 2024-01-12 JP JP2024003062A patent/JP2024056687A/ja not_active Withdrawn
-
2025
- 2025-09-18 US US19/333,297 patent/US20260015436A1/en active Pending
- 2025-12-10 JP JP2025244101A patent/JP2026062683A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| DK3781200T3 (da) | Antistoffer for chelaterede radionuklider | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| IL269240A (en) | Antibodies binding to vista at acidic ph | |
| EP3822289A4 (en) | ANTI-SIRP-ALPHA ANTIBODIES | |
| IL279894A (en) | Antibodies binding to ilt4 | |
| KR102763158B9 (ko) | 최적화된 항tl1a 항체 | |
| IL265321B1 (en) | Cd3 binding antibodies | |
| IL263840A (en) | Cd3 binding antibodies | |
| HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| IL272349A (en) | Anti-cd137 antibodies | |
| KR102355950B9 (ko) | Tigit에 대한 항체 | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| HUE051496T2 (hu) | TL1A-hoz specifikusan kötõdõ ellenanyagok | |
| PT3592384T (pt) | Anticorpos que se ligam especificamente ao il-1r7 humano | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL256097A (en) | Antibody epitope | |
| DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
| DK3484446T3 (da) | Antistofsammensætninger |